Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | HINT1 | P49773 | 3/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.47 |
| ▸ | KRAS | P01116 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12300425 | 0.90 | HPRT1 (0.55) | NT5EHPRT1TGM2HINT1TAS1R3 | |
| SCHEMBL8897427 | 0.89 | NT5E (0.65) | NT5EHPRT1TGM2HINT1FUT5 | |
| SCHEMBL12300464 | 0.87 | NT5E (0.58) | NT5EHPRT1TGM2HINT1FUT5 | |
| SCHEMBL21057089 | 0.86 | NT5E (0.61) | NT5EHPRT1TGM2HINT1FUT5 | |
| SCHEMBL12300513 | 0.84 | NT5E (0.55) | NT5EHINT1 | |
| SCHEMBL16409710 | 0.84 | NT5E (0.55) | NT5EHINT1 | |
| SCHEMBL12300444 | 0.84 | HPRT1 (0.40) | NT5EHPRT1TGM2TAS1R3TAS1R1 | |
| SCHEMBL12300460 | 0.84 | NT5E (0.59) | NT5EHPRT1TGM2HINT1FUT5 | |
| SCHEMBL21128140 | 0.84 | NT5E (0.57) | NT5EHPRT1TGM2HINT1FUT5 | |
| SCHEMBL21128395 | 0.84 | NT5E (0.57) | NT5EHPRT1TGM2HINT1FUT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | NT5E 203/4885HPRT1 106/4885TGM2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.